FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312053907> ?p ?o ?g. }

• W4312053907 endingPage "824.e3" @default.
• W4312053907 startingPage "817" @default.
• W4312053907 abstract "Relugolix treatment of advanced prostate cancer (APC), like other gonadotropin-releasing hormone-antagonists, results in rapid decrease in testosterone concentrations without the risk of flare, as seen in leuprolide. Despite this benefit over leuprolide, no economic evaluation assessment to ascertain the cost-effectiveness of relugolix has been conducted. Therefore, this study aims to assess the cost-effectiveness of androgen deprivation therapy (ADT) with 120 mg relugolix against 7.5 mg leuprolide for the treatment of APC.A Markov model was used to assess and compare the costs of APC treatment from a health care payer's perspective and the effectiveness of ADT with relugolix and leuprolide at the 3 lines of APC treatment among modified intent-to-treat patients. Relative progression-free (PFS) and overall survival (OS) rates were estimated. Outcomes measured in the analyses included costs of the drugs and therapies, quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), cost-effectiveness acceptability, and probability curves.The cost-effectiveness analysis showed the ICER for ADT with relugolix to be US $49,571.1 per QALY. At the ICER value, the sensitivity analysis indicated that ADT with leuprolide was dominant in 100% of the simulations. ADT acceptance with relugolix was 100% when a willingness-to-pay threshold was set at US $100,000/QALY. At 5-years, the relative PFS and OS rates for relugolix at the first line of therapy were 72.7% and 86.0%, respectively, compared to 61.0% and 85.90% for leuprolide.Though the influence of adverse events was not considered in the analysis, ADT with relugolix was not a cost-effective choice for APC management. While the analysis revealed a slight chance of sustaining testosterone suppression with relugolix, ADT with relugolix provided no significant survival advantages over ADT with leuprolide. Therefore, this analysis confirms no need for further assessment of APC interventions to make informed decisions beneficial to the APC patients, oncologists, and other stakeholders." @default.
• W4312053907 created "2023-01-04" @default.
• W4312053907 creator A5049473523 @default.
• W4312053907 creator A5064404725 @default.
• W4312053907 creator A5085687488 @default.
• W4312053907 date "2023-05-01" @default.
• W4312053907 modified "2023-10-18" @default.
• W4312053907 title "Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer" @default.
• W4312053907 cites W1555078472 @default.
• W4312053907 cites W1766746535 @default.
• W4312053907 cites W1966321188 @default.
• W4312053907 cites W2005709546 @default.
• W4312053907 cites W2005990105 @default.
• W4312053907 cites W2052147118 @default.
• W4312053907 cites W2052933214 @default.
• W4312053907 cites W2062070169 @default.
• W4312053907 cites W2065681165 @default.
• W4312053907 cites W2066554119 @default.
• W4312053907 cites W2074359547 @default.
• W4312053907 cites W2099037568 @default.
• W4312053907 cites W2156659229 @default.
• W4312053907 cites W2162460707 @default.
• W4312053907 cites W2556772293 @default.
• W4312053907 cites W2620746860 @default.
• W4312053907 cites W2920733634 @default.
• W4312053907 cites W2971916581 @default.
• W4312053907 cites W3032046986 @default.
• W4312053907 cites W4205145397 @default.
• W4312053907 cites W4293409513 @default.
• W4312053907 doi "https://doi.org/10.1016/j.japh.2022.12.019" @default.
• W4312053907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36653276" @default.
• W4312053907 hasPublicationYear "2023" @default.
• W4312053907 type Work @default.
• W4312053907 citedByCount "1" @default.
• W4312053907 countsByYear W43120539072023 @default.
• W4312053907 crossrefType "journal-article" @default.
• W4312053907 hasAuthorship W4312053907A5049473523 @default.
• W4312053907 hasAuthorship W4312053907A5064404725 @default.
• W4312053907 hasAuthorship W4312053907A5085687488 @default.
• W4312053907 hasConcept C112930515 @default.
• W4312053907 hasConcept C121608353 @default.
• W4312053907 hasConcept C126322002 @default.
• W4312053907 hasConcept C126894567 @default.
• W4312053907 hasConcept C143998085 @default.
• W4312053907 hasConcept C197934379 @default.
• W4312053907 hasConcept C2777899217 @default.
• W4312053907 hasConcept C2780192828 @default.
• W4312053907 hasConcept C29456083 @default.
• W4312053907 hasConcept C3019080777 @default.
• W4312053907 hasConcept C64332521 @default.
• W4312053907 hasConcept C71924100 @default.
• W4312053907 hasConceptScore W4312053907C112930515 @default.
• W4312053907 hasConceptScore W4312053907C121608353 @default.
• W4312053907 hasConceptScore W4312053907C126322002 @default.
• W4312053907 hasConceptScore W4312053907C126894567 @default.
• W4312053907 hasConceptScore W4312053907C143998085 @default.
• W4312053907 hasConceptScore W4312053907C197934379 @default.
• W4312053907 hasConceptScore W4312053907C2777899217 @default.
• W4312053907 hasConceptScore W4312053907C2780192828 @default.
• W4312053907 hasConceptScore W4312053907C29456083 @default.
• W4312053907 hasConceptScore W4312053907C3019080777 @default.
• W4312053907 hasConceptScore W4312053907C64332521 @default.
• W4312053907 hasConceptScore W4312053907C71924100 @default.
• W4312053907 hasIssue "3" @default.
• W4312053907 hasLocation W43120539071 @default.
• W4312053907 hasLocation W43120539072 @default.
• W4312053907 hasOpenAccess W4312053907 @default.
• W4312053907 hasPrimaryLocation W43120539071 @default.
• W4312053907 hasRelatedWork W2044284566 @default.
• W4312053907 hasRelatedWork W2244450389 @default.
• W4312053907 hasRelatedWork W2346894020 @default.
• W4312053907 hasRelatedWork W2582192498 @default.
• W4312053907 hasRelatedWork W2891070907 @default.
• W4312053907 hasRelatedWork W2912565296 @default.
• W4312053907 hasRelatedWork W4206404110 @default.
• W4312053907 hasRelatedWork W4285472650 @default.
• W4312053907 hasRelatedWork W4319748405 @default.
• W4312053907 hasRelatedWork W4380149576 @default.
• W4312053907 hasVolume "63" @default.
• W4312053907 isParatext "false" @default.
• W4312053907 isRetracted "false" @default.
• W4312053907 workType "article" @default.